A. Barry

发表

Precision and Accuracy of Fluconazole Susceptibility Testing by Broth Microdilution, Etest, and Disk Diffusion Methods

M. Pfaller, R. Rennie, A. Barry, 2002, Antimicrobial Agents and Chemotherapy.

Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic

R. Jones, A. Barry, P. Fuchs, 1990, Journal of clinical microbiology.

In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin againstStreptococcus pneumoniae as determined by three quantitative methods

A. Barry, P. Fuchs, S. Brown, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

Rapid Automated Antimicrobial Susceptibility Testing of Streptococcus pneumoniae by Use of the bioMerieux VITEK 2

J. Jorgensen, D. Sahm, A. Barry, 2000, Journal of Clinical Microbiology.

Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae

P. Murray, M. Ferraro, F. Tenover, 1996, Journal of clinical microbiology.

In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.

R. Jones, K. Aldridge, A. Barry, 1992, Diagnostic microbiology and infectious disease.

In Vitro Antimicrobial Activity of MSI-78, a Magainin Analog

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides againstStreptococcus pneumoniae andHaemophilus influenzae

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin

R. Jones, A. Barry, C. Thornsberry, 1988, Antimicrobial Agents and Chemotherapy.

Accuracy of the disk method for determining antimicrobic susceptibility of common Gram-negative bacilli

A. Barry, L. Effinger, 1979, Current Microbiology.

Simple inoculum standardizing system for antimicrobial disk susceptibility tests

M. Coyle, A. Barry, D. Amsterdam, 1979, Journal of clinical microbiology.

P-Lactams in Combination with Amdinocillin

P. Murray, R. Cleeland, H. Isenberg, 2022 .

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America.

A. Barry, A. Barry, 1999, The American journal of medicine.

Proposed disk diffusion susceptibility criteria for ofloxacin

R. Jones, A. Barry, P. Fuchs, 1985, Journal of clinical microbiology.

In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Comparison of six different criteria for judging the acceptability of sputum specimens

A. Barry, L. K. Wong, S. M. Horgan, 1982, Journal of clinical microbiology.

Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests

R. Jones, A. Barry, 1988, Journal of clinical microbiology.

Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks

H. Neu, J. Washington, J. Anhalt, 1985, Journal of clinical microbiology.

Identification of β-Lactamase-Negative, Ampicillin-Resistant Strains of Haemophilus influenzae with Four Methods and Eight Media

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates

R. Jones, A. Barry, P. Fuchs, 1984, Antimicrobial Agents and Chemotherapy.

Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability.

L. Ayers, R. Jones, A. Barry, 1985, Diagnostic microbiology and infectious disease.

Antimicrobial agents for community-acquired respiratory tract infections

A. Barry, 1995, Infection.

In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates

A. Barry, S. Brown, W. J. Novick, 1995, Antimicrobial agents and chemotherapy.

Binding of Cycloheximide to Ribosomes from Wild-Type and Mutant Strains of Saccharomyces cerevisiae

E. Goldstein, A. Barry, W. Piepersberg, 1981, Antimicrobial Agents and Chemotherapy.

In vitro potency of nine orally administered antimicrobial agents against three respiratory tract pathogens

A. Barry, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Susceptibility ofHaemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite

A. Barry, P. Fuchs, M. Pfaller, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method.

R. Jones, A. Barry, 1987, The Journal of antimicrobial chemotherapy.

In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin

R. Jones, A. Barry, C. Thornsberry, 1987, Antimicrobial Agents and Chemotherapy.

In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime.

Steven D. Brown, A. Barry, P. Fuchs, 2002, The Journal of antimicrobial chemotherapy.

Telithromycin. Author's Reply

D. Figgitt, J. Balfour, A. Barry, 2001 .

Antipneumococcal Activities of a Ketolide (HMR 3647), a Streptogramin (Quinupristin-Dalfopristin), a Macrolide (Erythromycin), and a Lincosamide (Clindamycin)

A. Barry, P. Fuchs, S. Brown, 1998, Antimicrobial Agents and Chemotherapy.

Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

Tracheobronchial flora in chronic obstructive pulmonary disease: preliminary results with authentic specimens and trial of trimethoprim-sulfamethoxazole.

T. Peirce, P. Hoeprich, A. Barry, 1973, The Journal of infectious diseases.

In-vitro studies of meropenem.

R. Jones, A. Barry, C. Thornsberry, 1989, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical Centers

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones.

A. Barry, P. Fuchs, S. Brown, 1996, Diagnostic microbiology and infectious disease.

Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole

M. Pfaller, A. Barry, D. Sewell, 1994, Journal of clinical microbiology.

In Vitro Activity of the Ketolide ABT-773

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group

A. Barry, P. Fuchs, S. Brown, 1997, Journal of clinical microbiology.

Interpretive criteria for temocillin disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1985, European Journal of Clinical Microbiology.

Susceptibility tests : diffusion test procedure

A. Barry, 1985 .

Reliability of the Kirby-Bauer disc diffusion method for detecting methicillin-resistant strains of Staphylococcus aureus.

J. Sherris, A. Barry, R. O'toole, 1972, Applied microbiology.

The antimicrobic susceptibility test : principles and practices

P. Hoeprich, A. Barry, M. Saubolle, 1976 .

Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions.

J. Rex, M. Pfaller, A. Barry, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

J. Rex, M. Pfaller, P. W. Nelson, 1995, Antimicrobial agents and chemotherapy.

The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.

R. Jones, A. Barry, R. R. Packer, 1989, Diagnostic microbiology and infectious disease.

In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method

A. Barry, M. Pfaller, M. Pfaller, 2005, Mycopathologia.

Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

M. Ghannoum, Steven D. Brown, J. Rex, 2000, Journal of Clinical Microbiology.

Antifungal Susceptibility Testing of Isolates from a Randomized, Multicenter Trial of Fluconazole versus Amphotericin B as Treatment of Nonneutropenic Patients with Candidemia

J. Rex, P. W. Nelson, A. Barry, 1994 .

Infective endocarditis caused by Streptococcus bovis resistant to the lethal effect of penicillin G.

P. Hoeprich, A. Barry, C. B. Savitch, 1978, Archives of internal medicine.

Improved 18-hour methyl red test.

A. Barry, L. Thrupp, A. P. Adams, 1970, Applied microbiology.

In vitro activity of Ro 23-9424, ceftazidime, and eight other newer beta-lactams against 100 gram-positive blood culture isolates.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

Rapid identification of Bacteroides fragilis with bile and antibiotic disks

A. Barry, D. Draper, 1977, Journal of clinical microbiology.

Rapid Identification ofBacteroides fragilis withBileand Antibiotic Disks

A. Barry, D. Draper, 1977 .

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

A. Barry, P. Fuchs, 1995, Antimicrobial agents and chemotherapy.

Four-hour urease test for distinguishing between Klebsiella and Enterobacter.

A. Barry, L. Thrupp, K. Bernsohn, 1969, Applied microbiology.

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora

M. Ghannoum, J. Galgiani, J. Rex, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1977, Antimicrobial Agents and Chemotherapy.

THE ROUTINE ANTIBIOTIC DISC-PLATE SENSITIVITY TESTS. I. VARIATIONS IN THE SIZE OF INOCULUM.

A. Barry, 1964, The American journal of medical technology.

Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.

A. Barry, P. Fuchs, S. Brown, 1998, The Journal of antimicrobial chemotherapy.

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993

A. Barry, P. Fuchs, M. Pfaller, 1994, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of the Ketolide HMR 3647 against Recent Gram-Positive Clinical Isolates and Haemophilus influenzae

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime

R. Jones, A. Barry, C. Thornsberry, 1989, Antimicrobial Agents and Chemotherapy.

In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.

A. Barry, P. Fuchs, S. Brown, 1999, Diagnostic microbiology and infectious disease.

Interpretive standards and quality control guidelines for imipenem susceptibility tests with 10-micrograms disks

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Multicenter in vitro evaluation of SM-7338, a new carbapenem

R. Jones, K. Aldridge, A. Barry, 1989, Antimicrobial Agents and Chemotherapy.

In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.

R. Jones, A. Barry, C. Thornsberry, 1989, The Journal of antimicrobial chemotherapy.

In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101

R. Jones, K. Aldridge, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219) -letter-.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

Interactions of Quinupristin-Dalfopristin with Eight Other Antibiotics as Measured by Time-Kill Studies with 10 Strains of Staphylococcus aureus for Which Quinupristin-Dalfopristin Alone Was Not Bactericidal

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity of Quinupristin-Dalfopristin against Staphylococcus aureus: Clindamycin Susceptibility as a Surrogate Indicator

Steven D. Brown, A. Barry, P. Fuchs, 2000, Antimicrobial Agents and Chemotherapy.

In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Surrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniae

A. Barry, P. Fuchs, 1996, Journal of clinical microbiology.

Reassessment of methods for testing the susceptibility of Haemophilus influenzae to clarithromycin.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test

P. Fernandes, J. Jorgensen, R. Jones, 1988, Journal of clinical microbiology.

Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.

R. Jones, A. Barry, 1987, The Pediatric infectious disease journal.

In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.

A. Barry, P. Fuchs, S. Brown, 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

Relative Potency of Telithromycin, Azithromycin and Erythromycin Against Recent Clinical Isolates of Gram-Positive Cocci

A. Barry, P. Fuchs, S. Brown, 2001, European Journal of Clinical Microbiology and Infectious Diseases.

Influence of Variations in Test Methods on Susceptibility of Haemophilus influenzae to Ampicillin, Azithromycin, Clarithromycin, and Telithromycin

Steven D. Brown, A. Barry, P. Fuchs, 2001, Journal of Clinical Microbiology.

Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

In vitro bactericidal activity of daptomycin against staphylococci.

Steven D. Brown, A. Barry, P. Fuchs, 2002, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Daptomycin against 2,789 Clinical Isolates from 11 North American Medical Centers

Steven D. Brown, A. Barry, P. Fuchs, 2001, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations

R. Jones, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin

A. Barry, P. Fuchs, S. Brown, 1996, European Journal of Clinical Microbiology and Infectious Diseases.

Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum

R. Jones, A. Barry, R. R. Packer, 1986, Antimicrobial Agents and Chemotherapy.

Antibacterial activity of fortimicin A compared with those of five other aminoglycosides, and factors affecting susceptibility tests

R. Jones, A. Barry, C. Baker, 1981, Antimicrobial Agents and Chemotherapy.

Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests

R. Jones, A. Barry, 1989, Journal of clinical microbiology.

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

R. Jones, J. Washington, K. Aldridge, 1988, Diagnostic microbiology and infectious disease.

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

Steven D. Brown, A. Barry, S. Brown, 1996, Antimicrobial agents and chemotherapy.

In vitro activity of the fluoroquinolone compounds

A. Barry, 1988 .

Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

R. Jones, A. Barry, 1983, Diagnostic microbiology and infectious disease.

Fluconazole disk diffusion procedure for determining susceptibility of Candida species

A. Barry, S. Brown, 1996, Journal of clinical microbiology.

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin

A. Barry, P. Fuchs, 1991, Antimicrobial Agents and Chemotherapy.

In-vitro methods for determining minimal lethal concentrations of antimicrobial agents.

A. Barry, R. A. Lasner, A. Barry, 1979, American journal of clinical pathology.

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

A review of some common sources of error in the preparation of agar media.

A. Barry, G. D. Fay, 1972, The American journal of medical technology.

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing

L. Ayers, R. Jones, A. Barry, 1982, Antimicrobial Agents and Chemotherapy.

Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Selection of a reference lot of Mueller-Hinton agar

A. Barry, P. Fuchs, H. Frankel, 1986, Journal of clinical microbiology.

Improved 18-Hour Methyl Red Test

A. Barry, L. Thrupp, A. P. Adams, 1970 .

Two Quick Methods for Voges-Proskauer Test

A. Barry, K. Feeney, 1967 .

TwoQuickMethods forVoges-Proskauer Test

A. Barry, K. Feeney, 1967 .

Determination of the ascorbic acid content of two medicinal plants in Nigeria.

L. Ayers, S. Brown, R. Jones, 2006 .

An improved single-disk method for testing the antibiotic susceptibility of rapidly-growing pathogens.

A. Barry, L. Thrupp, F. García, 1970, American journal of clinical pathology.

Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of Clinical Microbiology.

Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories

R. Jones, A. Barry, C. Thornsberry, 1981, Journal of clinical microbiology.

Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates

M. Pfaller, A. Barry, 1994, Journal of clinical microbiology.

Synthetic medium for susceptibility testing.

P. Hoeprich, A. Barry, G. D. Fay, 1970, Antimicrobial agents and chemotherapy.

Antimicrobic diffusion susceptibility tests on a defined medium solidified with a synthetic polymer (neutra-gel)

A. Barry, L. Effinger, 1978, Current Microbiology.

Reader error in determining minimal inhibitory concentrations with microdilution susceptibility test panels

A. Barry, L. E. Braun, 1981, Journal of clinical microbiology.

Quality Control Limits for the Agar Overlay Disk Diffusion Antimicrobial Susceptibility Test

A. Barry, R. Badal, 1982, Journal of clinical microbiology.

Anaerobic susceptibility tests with single breakpoint concentrations

A. Barry, 1990, European Journal of Clinical Microbiology and Infectious Diseases.

Disk diffusion and disk elution tests with A-56268 and erythromycin

R. Jones, A. Barry, C. Thornsberry, 1987, European Journal of Clinical Microbiology.

Criteria for in vitro susceptibility testing of cefotetan. Correlations with clinical and bacteriologic responses.

A. Barry, 1988, American journal of surgery.

Evaluation of in vitro methods for testing ceftriaxone against anaerobic bacteria, including quality control guidelines

R. Jones, A. Barry, 1988, Journal of Clinical Microbiology.

Ceftizoxime and cefoxitin susceptibility testing against anaerobic bacteria: comparison of results from three NCCLS methods and quality control recommendations for the reference agar dilution procedure.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Cefoperazone and cefoperazone-sulbactam susceptibility tests with anaerobic bacteria by the thioglycolate disk elution method

R. Jones, A. Barry, R. R. Packer, 1985, Journal of Clinical Microbiology.

Determination of susceptibility of anaerobic bacteria to cefotetan and cefoxitin by the thioglycolate disk elution method

A. Barry, R. R. Packer, 1984, Journal of clinical microbiology.

Collaborative evaluation of the micro-media systems anaerobe susceptibility panel: comparisons with reference methods and test reproducibility

R. Jones, A. Barry, J. Swenson, 1982, Journal of clinical microbiology.

Performances of Mueller-Hinton agars prepared by three manufacturers.

A. Barry, L. Effinger, 1974, American journal of clinical pathology.

Quality Control of Antimicrobial Disc Susceptibility Testing with a Rapid Method Compared to the Standard Methods

A. Barry, G. D. Fay, F. Atchison, 1972, Antimicrobial Agents and Chemotherapy.

Reliability of the microdilution technic for detection of methicillin-resistant strains of staphylococcus aureus.

A. Barry, R. Badal, 1977, American journal of clinical pathology.

Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.

R. Jones, A. Barry, P. Fuchs, 1982, Reviews of infectious diseases.

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Feasibility study of disk diffusion susceptibility tests with Mueller-Hinton broth solidified with Gelrite, an agar substitute

A. Barry, R. R. Packer, L. Creitz, 1985, Journal of clinical microbiology.

Methods of measuring zones of inhibition with the Bauer-Kirby disk susceptibility test

M. Coyle, A. Barry, C. Thornsberry, 1979, Journal of clinical microbiology.

Comparison ofBrothMacrodilution, BrothMicrodilution, and E TestAntifungal Susceptibility Tests forFluconazole

M. Pfaller, A. Barry, D. Sewell, 1994 .

Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965)

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Quality Control Parameters forSusceptibility Tests with30-,ug Netilmicin Disks

Ronald N. Jones, A. Barry, 1983 .

Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study

L. Reller, R. Jones, A. Barry, 1981, Journal of clinical microbiology.

3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1984, European Journal of Clinical Microbiology.

Proposed zone standards for interpretation of fortimicin A disk diffusion tests

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Evaluation of the Sensititre system for quantitative antimicrobial drug susceptibility testing: a collaborative study

R. Jones, A. Barry, T. Gavan, 1980, Antimicrobial Agents and Chemotherapy.

Evaluation of the Micro-Media System for Quantitative Antimicrobial Drug Susceptibility Testing: a Collaborative Study

R. Jones, A. Barry, T. Gavan, 1978, Antimicrobial Agents and Chemotherapy.

Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation.

R. Jones, A. Barry, C. Thornsberry, 1981, American journal of clinical pathology.

Netilmicin disk susceptibility tests: Effect of cations on the MIC correlates

R. Jones, A. Barry, C. Thornsberry, 1987, European Journal of Clinical Microbiology.

Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo

R. Jones, R. Ferraresi, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

Azlocillin, a ureido penicillin active against Pseudomonas aeruginosa: interpretive zone standards and quality control parameters for tests with 75-mu g disks

R. Jones, A. Barry, C. Thornsberry, 1982, Journal of clinical microbiology.

Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test

R. Jones, A. Barry, C. Thornsberry, 1981, Antimicrobial Agents and Chemotherapy.

Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Cross-resistance and cross-susceptibility between fluoroquinolone agents

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid.

A. Barry, R. R. Packer, R. Gardiner, 1987, Diagnostic microbiology and infectious disease.

In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits.

R. Jones, A. Barry, P. Fuchs, 1985, Diagnostic microbiology and infectious disease.

Evaluation of the MICUR system for quantitative antimicrobial susceptibility testing: a multiphasic comparison with reference methods

R. Jones, A. Barry, C. Thornsberry, 1982, Journal of clinical microbiology.

Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria

T. Wilkins, A. Barry, V. Sutter, 1979, Antimicrobial Agents and Chemotherapy.

Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria.

R. Jones, K. Aldridge, A. Bourgault, 1990, Reviews of infectious diseases.

An in vitro evaluation of HRE 664, a novel penem antibiotic.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Collaborative Evaluation ofaProposed Reference Dilution MethodofSusceptibility Testing ofAnaerobic Bacteria

A. Barry, V. Sutter, 1979 .

Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1988, Journal of clinical microbiology.

Stability of antimicrobials in Schaedler's anaerobic and brain heart infusion broths stored at --20 degrees C.

R. Jones, A. Barry, P. Fuchs, 1978, The Journal of antibiotics.

In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone

R. Jones, A. Barry, 1990, Antimicrobial Agents and Chemotherapy.

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Influence of the test medium on azithromycin and erythromycin regression statistics

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin

A. Barry, C. Thornsberry, T. Gavan, 1989, European Journal of Clinical Microbiology and Infectious Diseases.

Evaluation of the Sceptor microdilution antibiotic susceptibility testing system: a collaborative investigation

R. Jones, A. Barry, C. Thornsberry, 1981, Journal of clinical microbiology.

Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.

R. Jones, K. Aldridge, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition.

R. Jones, A. Barry, P. Fuchs, 1982, The Journal of antimicrobial chemotherapy.

Evaluation of four disk diffusion methods for antimicrobic susceptibility tests with anaerobic gram-negative bacilli.

A. Barry, G. D. Fay, 1974, American journal of clinical pathology.

Collaborative evaluation of the microbial profile system for quantitative antimicrobial susceptibility testing

R. Jones, A. Barry, E. Gerlach, 1983, Journal of clinical microbiology.

Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum

R. Jones, A. Barry, 1987, Antimicrobial Agents and Chemotherapy.

Evaluation of teicoplanin and vancomycin disk susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1986, Journal of clinical microbiology.

In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

R. Jones, A. Barry, 1989, The Journal of antimicrobial chemotherapy.

Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

R. Jones, A. Barry, A. Barry, 1989, Diagnostic microbiology and infectious disease.

Emergence of Streptococcus faecalis isolates with high-level resistance to multiple aminocyclitol aminoglycosides.

A. Barry, D. Ikeda, S. G. Andersen, 1984, Diagnostic microbiology and infectious disease.

Reliability of early identifications obtained with Enterobacteriaceae-plus biochemical cards in the automicrobic system

A. Barry, R. Badal, 1982, Journal of clinical microbiology.

Sensitivity, specificity, and reproducibility of the automicrobic system (with the Enterobacteriaceae-plus biochemical card) for identifying clinical isolates of Gram- negative bacilli

A. Barry, R. Badal, T. Gavan, 1982, Journal of clinical microbiology.

Inter- and intralaboratory variability in antibiotic susceptibility tests with Pseudomonas aeruginosa and Enterobacteriaceae.

T. O'Brien, A. Barry, J. Matsen, 1976, The Journal of infectious diseases.

Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1984, Journal of clinical microbiology.

Special tests:bacteriocidal activity, activity of antimicrobials in combination adn detection of bets-lactamase production

J. Anhalt, A. Barry, L. Sabath, 1980 .

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

R. Jones, A. Barry, P. Fuchs, 1981, The Journal of antimicrobial chemotherapy.

Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)

R. Jones, A. Barry, 1988, Antimicrobial Agents and Chemotherapy.

Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin

A. Barry, P. Fuchs, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolates

L. Ayers, R. Jones, A. Barry, 1986, Antimicrobial Agents and Chemotherapy.

Influence of inoculum growth phase on microdilution susceptibility tests

A. Barry, R. Badal, R. Hawkinson, 1983, Journal of clinical microbiology.

Evaluation of the sensititre microdilution antibiotic susceptibility system against recent clinical isolates: three-laboratory collaborative study

R. Jones, A. Barry, T. Gavan, 1980, Journal of clinical microbiology.

In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci

R. Jones, A. Barry, 1990, Antimicrobial Agents and Chemotherapy.

Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid. Evaluation of oxacillin-resistant and oxacillin-susceptible isolates.

A. Barry, 1990, Diagnostic microbiology and infectious disease.

Evaluation of a proprietary broth medium for microdilution susceptibility testing of nutritionally fastidious bacteria

R. Jones, A. Barry, J. Cotton, 1986, Journal of clinical microbiology.

Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

R. Jones, A. Barry, C. Thornsberry, 1982, Reviews of infectious diseases.

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

Ronald N. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.

R. Jones, A. Barry, C. Thornsberry, 1986, Diagnostic microbiology and infectious disease.

The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.

R. Jones, A. Barry, R. R. Packer, 1984, Diagnostic microbiology and infectious disease.

Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics.

R. Jones, A. Barry, 1983, Reviews of infectious diseases.

In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides.

R. Jones, A. Barry, C. Thornsberry, 1980, Cleveland Clinic quarterly.

In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides.

R. Jones, A. Barry, C. Thornsberry, 1980, The Journal of antimicrobial chemotherapy.

Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

R. Jones, A. Barry, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

R. Jones, A. Barry, P. Fuchs, 1985, Antimicrobial Agents and Chemotherapy.

Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.

R. Jones, A. Barry, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Desacetylcefotaxime--another broad spectrum cephalosporin?

L. Ayers, R. Jones, A. Barry, 1989, The Journal of antimicrobial chemotherapy.

Activity of six contemporary antibacterial agents against 96 isolates from purulent meningitis: the contribution of desacetylcefotaxime to antimicrobial potency.

R. Jones, A. Barry, 1987, The Journal of antimicrobial chemotherapy.

Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium

R. Jones, A. Barry, 1983, Antimicrobial Agents and Chemotherapy.

Survey of antimicrobial activity of four commonly used third generation cephalosporins tested against recent bacterial isolates from ten American medical centers, and assessment of disk diffusion test performance. AST Surveillance Group.

A. Barry, P. Fuchs, S. Brown, 1996, Diagnostic microbiology and infectious disease.

Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-μg disks

Ronald N. Jones, A. Barry, C. Thornsberry, 1983 .

Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935)

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Cefoperazone: evaluation of the in vitro activity and an analysis of the disk diffusion test.

R. Jones, A. Barry, C. Baker, 1980, Clinical therapeutics.

Proposed Quality Control Guidelines

Ronald N. Jones, A. Barry, C. Thornsberry, 2016 .

Antimicrobial Susceptibility Testing of Cefoperazone

Ronald N. Jones, A. Barry, C. Baker, 2003 .

Bacterial antibiotic resistance before and after clinical application in the United States.

R. Jones, A. Barry, 1987, Bulletin of the New York Academy of Medicine.

In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studies

Ronald N. Jones, A. Barry, C. Thornsberry, 1985 .

Temocillin: in vitro activity against 734 selected clinical isolates, including beta-lactamase-producing strains.

R. Jones, A. Barry, P. Fuchs, 1984, Diagnostic microbiology and infectious disease.

In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits

A L Barry, R N Jones, T L Gavan, 1983, Antimicrobial Agents and Chemotherapy.

Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone

R. Jones, A. Barry, C. Baker, 1982, Journal of clinical microbiology.

Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits

R. Jones, A. Barry, D. Gibbs, 1982, Journal of clinical microbiology.

BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides

L. Peterson, L. Reller, J. Washington, 1992, Journal of clinical microbiology.

Feasibility StudyofDiskDiffusion Susceptibility TestswithMueller- Hinton BrothSolidified withGelrite, an AgarSubstitute

A. Barry, R. R. Packer, L. Creitz, 1985 .

Rapid determination of antimicrobial susceptibility for urgent clinical situations.

E. Benner, A. Barry, L. Joyce, 1973, American journal of clinical pathology.

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination

R. Jones, A. Barry, C. Thornsberry, 1987, Journal of clinical microbiology.

Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue

J. Meis, M. Pfaller, D. Ellis, 2004, Journal of Clinical Microbiology.

Quality Control Limits for Fluconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue

J. Meis, M. Pfaller, D. Ellis, 2003, Journal of Clinical Microbiology.

Short-Term Storage ofSixPenicillins andCephalothin in Microdilution Trays forAntimicrobial Susceptibility Tests

A. Barry, R. Badal, L. Effinger, 1976 .

Performance of Mueller-Hinton Agars Prepared by Three Different Manufacturers

A. Barry, L. Effinger, 1974 .

A system for reporting quantitative antimicrobic susceptibility test results.

A. Barry, 1979, American journal of clinical pathology.

Roxithromycin bioassay procedures for human plasma, urine and milk specimens

A. Barry, R. R. Packer, 1986, European Journal of Clinical Microbiology.

Broth Medium for Microdilution Susceptibility Tests of Fluconazole and Voriconazole

A. Barry, S. Brown, M. Traczewski, 2002, European Journal of Clinical Microbiology and Infectious Diseases.

Two quick methods for Voges-Proskauer test.

A. Barry, K. Feeney, 1967, Applied microbiology.

An Overview of the Clinical and Laboratory Standards Institute (CLSI) and Its Impact on Antimicrobial Susceptibility Tests

A. Barry, 2007 .

DIAGNOSTIC PARASITOLOGY—Clinical Laboratory Manual

A. Barry, 1976 .

Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test

A L Barry, J A Washington, J. Washington, 1996, Journal of clinical microbiology.

Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.

A. Barry, P. Fuchs, S. Brown, 2001, The Journal of antimicrobial chemotherapy.

Preparation of amniotic membranes for surgical use with antibiotic solutions.

A. Barry, J. Trelford, W. L. Gannaway, 1984, Surgery.

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Four-Hour Urease Test for Distinguishing Between Klebsiella and Enterobacter

A. Barry, L. Thrupp, K. Bernsohn, 1969 .

Standardization of Broth Microdilution and Disk Diffusion Susceptibility Tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: Quality Control Standards for Ceftiofur, Enrofloxacin, Florfenicol, Gentamicin, Penicillin, Tetracycline, Tilmicosin, and Trimethoprim-Sulfamethoxazole

P. McDermott, G. Stein, R. Jones, 2001, Journal of Clinical Microbiology.

Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests

A. Barry, P. Fuchs, S. Brown, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro evaluation of A-56619 and A-56620, two new quinolones

A L Barry, R N Jones, C Thornsberry, 1986, Antimicrobial Agents and Chemotherapy.

In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations

A. Barry, P. Fuchs, P. Anderson, 1991, Antimicrobial Agents and Chemotherapy.

In vitro susceptibility testing procedures for fosfomycin tromethamine

A. Barry, P. Fuchs, 1991, Antimicrobial Agents and Chemotherapy.

Selection of Zone Size Interpretive Criteria for Disk Diffusion Susceptibility Tests of Three Antibiotics against Streptococcus pneumoniae, Using the New Guidelines of the National Committee for Clinical Laboratory Standards

Steven D. Brown, A. Barry, P. Fuchs, 2002, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin

R. Jones, A. Barry, C. Baker, 1980, Antimicrobial Agents and Chemotherapy.

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid

A. Barry, P. Fuchs, M. Pfaller, 1993, Antimicrobial Agents and Chemotherapy.

Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group

R. Jones, A. Barry, 1990, Journal of clinical microbiology.

Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin

R. Jones, A. Barry, A. L. Barry, 1988, Antimicrobial Agents and Chemotherapy.

Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics

R. Jones, A. Barry, C. Baker, 1980, Antimicrobial Agents and Chemotherapy.

Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1979, Antimicrobial Agents and Chemotherapy.

In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.

A. Barry, P. Fuchs, S. Brown, 2000, Diagnostic microbiology and infectious disease.

Staphylococcal myositis in a compromised host. Successful treatment with the synergistic combination of nafcillin and gentamicin.

A. Barry, G. Jordan, G. A. Wong, 1976, The Western journal of medicine.

Rapid Ornithine Decarboxylase Test for the Identification of Enterobacteriaceae

A. Barry, G. D. Fay, 1972 .

1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1978, Current Microbiology.

Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test

R. Jones, A. Barry, 1987, European Journal of Clinical Microbiology.

In Vitro Evaluation of HR810, a New Wide-Spectrum Aminothiazolyl α-Methoxyimino Cephalosporin

Ronald N. Jones, A. Barry, C. Thornsberry, 1984, Antimicrobial Agents and Chemotherapy.

In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs

R. Jones, A. Barry, C. Thornsberry, 1983, Antimicrobial Agents and Chemotherapy.

Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1977, The American journal of the medical sciences.

BL-S786, A NEW PARENTERAL CEPHALOSPORIN. I

Ronald N. Jones, A. Barry, P. Fuchs, 1977 .

Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group

A. Barry, P. Fuchs, S. Brown, 1996, Antimicrobial agents and chemotherapy.

Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.

D. Citron, A. Barry, P. Fuchs, 1993, The Journal of antimicrobial chemotherapy.

Cefpiramide: comparative in-vitro activity and β-lactamase stability

Ronald N. Jones, L. Ayers, A. Barry, 1985 .

In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin

R. Jones, A. Barry, C. Thornsberry, 1984, Antimicrobial Agents and Chemotherapy.

Roxithromycin bioassay procedures for human plasma, urine and milk specimens

A. Barry, R. R. Packer, 2005, European Journal of Clinical Microbiology.

Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides

R. Jones, A. Barry, 1987, European Journal of Clinical Microbiology.

Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition.

R. Jones, A. Barry, C. Thornsberry, 1982, The Journal of antimicrobial chemotherapy.

Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

R. Jones, A. Barry, P. Fuchs, 1979, American journal of clinical pathology.

Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis.

R. Jones, A. Barry, P. Fuchs, 1979, The Journal of antibiotics.

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories

L. Ayers, R. Jones, A. Barry, 1984, Journal of clinical microbiology.

Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters

P. Murray, F. Tenover, J. Jorgensen, 1993, Journal of clinical microbiology.

Proposed interpretive criteria and quality control parameters for ofloxacin susceptibility testing of Neisseria gonorrhoeae

P. Murray, J. Washington, A. Barry, 1992, Journal of clinical microbiology.

Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-μg disks

Ronald N. Jones, A. Barry, 1987 .

Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.

R. Jones, A. Barry, C. Thornsberry, 1985, Reviews of infectious diseases.

Short-Term Storage of Six Penicillins and Cephalothin in Microdilution Trays for Antimicrobial Susceptibility Tests

A. Barry, R. Badal, L. Effinger, 1976, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of LY163892, an orally administered 1-carbacephem.

R. Jones, A. Barry, 1988, The Journal of antimicrobial chemotherapy.

PMX-622 (Polymyxin B-Dextran 70) Does Not Alter In Vitro Activities of 11 Antimicrobial Agents

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays

A. Barry, R. Badal, 2007, Current Microbiology.

Sensitivity, Specificity, andReproducibility ofthe AutoMicrobic System (with theEnterobacteriaceae-Plus Biochemical Card) forIdentifying Clinical Isolates ofGram- Negative Bacilli

A. Barry, Andmary J. Telenson, 1982 .

Evaluation of Two Standardized Disk Methods for Testing Antimicrobial Susceptibility of Pseudomonas aeruginosa and of the Enterobacteriaceae

A. Barry, L. Effinger, 1974, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

R. Jones, A. Barry, P. Fuchs, 1980, Clinical therapeutics.

Cefuroxime, an in vitro Comparison with Six Other Cephalosporins

R. Jones, A. Barry, P. Fuchs, 1977, Proceedings of the Royal Society of Medicine.

In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.

D. Hardy, A. Barry, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Identification of Enterobacteriaceae in frozen microdilution trays prepared by Micro-Media Systems

A. Barry, R. Badal, L. Effinger, 1979, Journal of clinical microbiology.

Detection of staphylococcal resistance to penicillinase-resistant penicillins. A comparison of two widely used disk diffusion methods.

R. Jones, A. Barry, 1989, Diagnostic microbiology and infectious disease.

Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria

A L Barry, R N Jones, T L Gavan, 1987, Journal of clinical microbiology.

Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.

A. Barry, P. Fuchs, S. Brown, 1997, Journal of chemotherapy.

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

Steven D. Brown, A. Barry, P. Fuchs, 2000, Diagnostic microbiology and infectious disease.

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.

A. Barry, P. Fuchs, S. Brown, 2001, The Journal of antimicrobial chemotherapy.

Multicenter survey of the in vitro activity of four expanded-spectrum beta-lactams against consecutive contemporary clinical isolates.

A. Barry, P. Fuchs, S. Brown, 1998, Diagnostic microbiology and infectious disease.

Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination

R. Jones, A. Barry, 1988, Journal of clinical microbiology.

Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

R. Jones, A. Barry, R. R. Packer, 1986, Journal of Antimicrobial Chemotherapy.

The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.

R. Jones, A. Barry, C. Thornsberry, 1985, American Journal of Clinical Pathology.

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent

R. Jones, A. Barry, W. J. Novick, 1982, Journal of clinical microbiology.

Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Cefixime Disk Susceptibility Test Criteria

R. Jones, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

In vitro activity and disk susceptibility of Timentin: current status.

R. Jones, A. Barry, P. Fuchs, 1985, The American journal of medicine.

Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Evaluation of the cefonicid disk test criteria, including disk quality control guidelines

R. Jones, A. Barry, C. Thornsberry, 1983, Journal of clinical microbiology.

In-vitro activity of five β-lactam/β-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1994 .

Error rates in cefoperazone and cefoperazone-sulbactam disk tests withenterobacteriaceae andPseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks

R. Jones, A. Barry, C. Thornsberry, 1984, Journal of clinical microbiology.

Ceftibuten (7432-S, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines

R. Jones, A. Barry, The Collaborative Antimicrobial Susceptibility Testing Group, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro antimicrobial activity of tigemonam, a new orally administered monobactam

R. Jones, A. Barry, P. Fuchs, 1988, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.

L. Ayers, R. Jones, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination

R. Jones, A. Barry, 1987, Journal of clinical microbiology.

Quality control limits for microdilution susceptibility tests with norfloxacin

L. Ayers, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter study.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Effect of beta-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic beta-lactamase producing bacteria.

R. Jones, A. Barry, P. Fuchs, 1987, Diagnostic microbiology and infectious disease.

Comparison ofSixDifferent Criteria forJudging the Acceptability ofSputumSpecimens

A. Barry, L. K. Wong, S. M. Horgan, 1982 .

In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents

A. Barry, P. Fuchs, S. Brown, 1996, Antimicrobial agents and chemotherapy.

In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition.

R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin

R. Jones, A. Barry, C. Thornsberry, 1981, Antimicrobial Agents and Chemotherapy.

Unpredictable interactions between cefotetan and penicillins or aminoglycosides.

R. Jones, A. Barry, R. R. Packer, 1984, Diagnostic microbiology and infectious disease.

The antibacterial activity of co-amoxiclav.

A. Barry, P. Fuchs, M. Pfaller, 1993, The Journal of antimicrobial chemotherapy.

Interpretative criteria for the agar diffusion susceptibility test with azithromycin.

R. Jones, A. Barry, 1988, The Journal of antimicrobial chemotherapy.

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

In Vitro Activities of Clinafloxacin against Contemporary Clinical Bacterial Isolates from 10 North American Centers

Steven D. Brown, A. Barry, P. Fuchs, 1998, Antimicrobial Agents and Chemotherapy.

Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.

R. Jones, A. Barry, C. Baker, 1979, The Journal of antibiotics.

Rapid identification of Escherichia, Klebsiella, and Enterobacter by use of a new urease test.

A. Barry, L. Thrupp, K. L. Bernhn, 1968, Antimicrobial agents and chemotherapy.

Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

A. Barry, P. Fuchs, M. Pfaller, 1991, Antimicrobial Agents and Chemotherapy.

The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam.

R. Jones, A. Barry, P. Fuchs, 1986, American journal of clinical pathology.

Susceptibility of bacterial respiratory pathogens to amoxicillin and amoxicillin-clavulanic acid

A. Barry, P. Fuchs, Peter C. Fuchs, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

Methods for storing oxidase test reagents.

A. Barry, K. Bernsohn, 1969, Applied microbiology.

The amount of agar in antimicrobic disk susceptibility test plates.

A. Barry, G. D. Fay, 1973, American Journal of Clinical Pathology.

Interpretive criteria for antimicrobial susceptibility tests with cefodizime discs.

A. Barry, P. Fuchs, 1991, The Journal of antimicrobial chemotherapy.

Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

A. Barry, P. Fuchs, S. Brown, 2000, Diagnostic microbiology and infectious disease.

Quality control parameters for cefditoren susceptibility tests.

A. Barry, P. Fuchs, S. Brown, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Performance of Haemophilus Test Media prepared with 12 different lots of Mueller-Hinton agar from four manufacturers

A. Barry, R. R. Packer, 1992, Journal of clinical microbiology.

Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain

P. Murray, M. Ferraro, G. Doern, 1992, Journal of clinical microbiology.

Reproducibility of disc susceptibility tests with Haemophilus influenzae.

J. Jorgensen, D. Hardy, A. Barry, 1991, The Journal of antimicrobial chemotherapy.

Rapid ornithine decarboxylase test for the identification of enterobacteriaceae.

A. Barry, G. D. Fay, 1972, Applied microbiology.

Reproducibility of three microdilution systems for identification of enterobacteriaceae, compared with API 20E and micro-ID test systems

A. Barry, R. Badal, L. Effinger, 2007, Current Microbiology.

Methods for Detecting Carbohydrate Fermentation by Gram-Negative Nonsporeforming Anaerobes

A. Barry, G. D. Fay, 1974 .

Methods for Detecting Indole Production by Gram-Negative Nonsporeforming Anaerobes

A. Barry, G. D. Fay, 1974 .

Methods for detecting indole production by gram-negative nonsporeforming anaerobes.

A. Barry, G. D. Fay, 1974, Applied microbiology.

Methods for detecting carbohydrate fermentation by gram-negative nonsporeforming anaerobes.

A. Barry, G. D. Fay, 1974, Applied microbiology.

Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin

P. Murray, J. Washington, A. Barry, 1991, Journal of clinical microbiology.

Proposed interpretive criteria and quality control parameters for testing susceptibility of Neisseria gonorrhoeae to beta-lactam-clavulanate combinations

P. Murray, J. Washington, A. Barry, 1992, Journal of clinical microbiology.

Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?

A. Barry, P. Fuchs, S. Brown, 1997, The Journal of antimicrobial chemotherapy.

Methods for Storing Oxidase Test Reagents

A. Barry, K. Bernsohn, 1969 .

Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399

A. Barry, P. Fuchs, M. Pfaller, 1993, Antimicrobial Agents and Chemotherapy.

Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Reliability of the Kirby-Bauer Disc Diffusion Method for Detecting Methicillin-Resistant Strains of Staphylococcus aureus

J. Sherris, A. Barry, R. O'toole, 1972 .

Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin

A. Barry, P. Fuchs, M. Pfaller, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Identification of Staphylococcus aureus by simultaneous use of tube coagulase and thermonuclease tests.

A. Barry, R. Lachica, F. Atchison, 1973, Applied microbiology.

Tentative disk diffusion susceptibility interpretive criteria for pefloxacin

R. Jones, A. Barry, P. Fuchs, 1986, Journal of clinical microbiology.

Identification of Staphylococcus aureus by Simultaneous Use of Tube Coagulase and Thermonuclease Tests

A. Barry, R. Lachica, F. Atchison, 1973 .

Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.

A. Barry, P. Fuchs, 1991, The Journal of antimicrobial chemotherapy.

In vitro activity of ciprofloxacin against gram-positive cocci.

R. Jones, A. Barry, 1987, The American journal of medicine.

A three category system for interpretation of disk tests for Pseudomonas-active penicillins and beta-lactamase hydrolysis/inhibition studies.

R. Jones, A. Barry, 1982, Journal of Antimicrobial Chemotherapy.

Apalcillin (PC-904): Spectrum of activity and β-lactamase hydrolysis/inhibition

Ronald N. Jones, A. Barry, C. Thornsberry, 1985 .

Antibacterial spectrum of fosfomycin trometamol.

A. Barry, S. Brown, 1995, Journal of Antimicrobial Chemotherapy.

Susceptibility testing quality control studies with fosfomycin tromethamine

A. Barry, P. Fuchs, S. Brown, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods.

A. Barry, P. Fuchs, S. Brown, 1999, The Journal of antimicrobial chemotherapy.

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine

F. Tenover, L. Reller, D. Hardy, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Evaluation of disk susceptibility testing of fosfomycin tromethamine.

A. Barry, P. Fuchs, M. Pfaller, 1993, Diagnostic microbiology and infectious disease.

Pneumococcal susceptibility to meropenem.

A. Barry, P. Fuchs, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628

F. Tenover, L. Reller, J. Jorgensen, 1995, Journal of clinical microbiology.

Eubacterium lentum ATCC 43055, a new reference strain for quality control of anaerobic susceptibility tests

A. Barry, R. Zabransky, 1990, Journal of clinical microbiology.

In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Piperacillin susceptibility tests by the single-disk agar diffusion technique

R. Jones, A. Barry, C. Baker, 1979, Antimicrobial Agents and Chemotherapy.

Efficiency of a transport medium for the recovery of aerobic and anaerobic bacteria from applicator swabs.

R. L. Sauer, A. Barry, G. D. Fay, 1972, Applied microbiology.

In vitro interaction between the penem FCE 22101 and ceftazidime

R. Jones, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones

R. Jones, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.

F. Tenover, J. Jorgensen, A. Barry, 1996, The Journal of antimicrobial chemotherapy.

Rapid identification of Enterobacteriaceae with the micro-ID system versus API 20E and conventional media

A. Barry, R. Badal, 1979, Journal of clinical microbiology.

Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents

A. Barry, 1988, Antimicrobial Agents and Chemotherapy.

Anaerobic activity of levofloxacin and metronidazole separately and in combination.

A. Barry, S. Brown, 1996, The Journal of antimicrobial chemotherapy.

Accuracy and precision of the autobac system for rapid identification of Gram-negative bacilli: a collaborative evaluation

B. Sielaff, P. Smith, A. Barry, 1982, Journal of clinical microbiology.

Accuracy andPrecision oftheAutobac System forRapid Identification ofGram-Negative Bacilli: aCollaborative Evaluation

P. Smith, A. Barry, J. Matsen, 1982 .

Identification of Enterobacteriaceae by the automicrobic system: Enterobacteriaceae biochemical cards versus Enterobacteriaceae-plus biochemical cards

A. Barry, R. Badal, 1982, Journal of clinical microbiology.

Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species

A. Barry, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics.

A. Barry, P. Fuchs, S. Brown, 1995, The Journal of antimicrobial chemotherapy.

RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.

A. Barry, P. Fuchs, M. Pfaller, 1993, The Journal of antimicrobial chemotherapy.

Prevalence of ticarcillin/clavulanic acid-resistant Enterobacteriaceae in nine separate medical centers during the years 1983, 1989, and 1991.

A. Barry, 1994, Advances in experimental medicine and biology.

Efficiency of a Transport Medium for the Recovery of Aerobic and Anaerobic Bacteria from Applicator Swabs

R. L. Sauer, A. Barry, G. D. Fay, 1972 .

Antimicrobial activity of imipenem and SCH34343 against Legionella species.

R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Reliability of high-content disks and modified broth dilution tests for detecting staphylococcal resistance to the penicillinase-resistant penicillins

R. Jones, A. Barry, 1987, Journal of Clinical Microbiology.

Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae

D. Hardy, A. Barry, P. Fuchs, 1992, Antimicrobial Agents and Chemotherapy.

In-vitro potency of azithromycin against gram-negative bacilli is method-dependent.

A. Barry, P. Fuchs, 1991, Journal of Antimicrobial Chemotherapy.

Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam

D. Hardy, A. Barry, P. Fuchs, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Parameters for quality control of antimicrobial susceptibility tests of roxithromycin.

Steven D. Brown, A. Barry, 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.